NASDAQ:ZNTL

Zentalis Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy ZNTL

*Your capital is at risk

$4.74

-0.180 (-3.66%)

At Close: Jul 31, 2026

Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

07:00am, Thursday, 12'th Aug 2021

Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles

Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma

07:30am, Monday, 02'nd Aug 2021

NEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule

Zentera Therapeutics Announces Closing of $75 Million Series B Financing

07:00am, Monday, 02'nd Aug 2021

Proceeds will be used to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China Proceeds will be used

Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

04:01pm, Thursday, 01'st Jul 2021

NEW YORK and SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule

Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock

09:09pm, Monday, 28'th Jun 2021

NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule

Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock

04:18pm, Monday, 28'th Jun 2021

Zentalis Pharmaceuticals to Participate in the Jefferies Virtual Healthcare Conference

07:00am, Friday, 28'th May 2021

NEW YORK and SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule

Zentalis's Early WEE1 Inhibitor Data Shows 'Exceptional' Response In Solid Tumor Study, Plans Combination Trials

11:18am, Monday, 12'th Apr 2021

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) has announced initial efficacy and safety data from the Phase 1 dose-escalation portion of its ongoing Phase 1/2 trial evaluating ZN-c3 in patients with

Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor

07:00am, Monday, 12'th Apr 2021

ZN-c3 is currently being evaluated in patients with advanced solid tumors and ovarian cancer ZN-c3 is currently being evaluated in patients with advanced solid tumors and ovarian cancer

Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors

01:30pm, Saturday, 10'th Apr 2021

ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

07:00am, Thursday, 25'th Mar 2021

Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 and BCL-2 inhibitor, ZN-d5

Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021

04:30pm, Wednesday, 10'th Mar 2021

Additional preclinical data on ZN-c3 and the Company's EGFR inhibitor, ZN-e4, will be presented as poster presentations Additional preclinical data on ZN-c3 and the Company's EGFR inhibitor, ZN-e4, wi

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by